SUBSCRIBERS
Some bladder cancer patients benefit from Roche therapy
Published Mon, Jun 6, 2016 · 09:50 PM
Chicago
A NEWLY approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.
Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become the first option therapy of choice for patients with metastatic bladder cancer, according to a researcher leading the study.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue